Clinical features of patients with pancreatic ductal adenocarcinoma with a history of other primary malignancies: A retrospective analysis

被引:1
|
作者
Hayashi, Hironori [1 ]
Amaya, Koji [1 ]
Tokoro, Tomokazu [1 ]
Mori, Kosuke [1 ]
Takenaka, Shunsuke [1 ]
Sugimoto, Yuya [1 ]
Kitano, Yuto [1 ]
Kurata, Toru [1 ]
Kawai, Shunsuke [1 ]
Hirose, Atsushi [1 ]
Tsukada, Tomoya [1 ]
Kaji, Masahide [1 ]
Shimizu, Koichi [2 ]
Maeda, Kiichi [1 ]
机构
[1] Toyama Prefectural Cent Hosp, Dept Surg, 2-2-78 Nishi Nagae, Toyama 9308550, Japan
[2] Kaga Med Ctr, Dept Surg, Kaga, Ishikawa 9228522, Japan
关键词
cancer genomics; epidemiology; multiple primary malignancies; pancreatic ductal adenocarcinoma; prognosis; surgical treatment; CANCER PATIENTS; ORGANS; IMPACT;
D O I
10.3892/mco.2021.2.335
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Patients with pancreatic ductal adenocarcinoma (PDAC) that have a history of other primary malignancies are not well documented. The current study therefore aimed to evaluate the dinicopathological characteristics of patients with PDAC with or without a history of other primary malignancies. A total of 102 patients with surgically treated PDAC that presented with or without a history of other primary malignancies were retrospectively analyzed. A total of 25 patients (24.5%) had a history of other primary malignancies (age, with history of other primary malignancy vs. without, 74.2 vs. 68.9 years; P=0.005) and the reason for consultation (P<0.001) differed significantly between the groups with a history of other primary malignancies [FloM(+)] and without a history of other primary malignancies [HOMO]. Incidental indications during malignancy follow-up was the most common reason for the diagnosis of PDAC in the HoM(+) group. Conversely, there were no significant differences in the resectability (P=0.645), complete resection rate (P=0.774) and final stage (P=0.474) between the two groups. Disease-free survival was also not significantly different between the two groups (P=0.184). However, overall survival was significantly poorer in the HoM(+) group compared with the HoM(-) group (P=0.003). A history of other primary malignancies was also an independent predictor of poor overall survival (hazard ratio, 2.416; 95% confidence interval, 1.324-4.406; P=0.004). In conclusion, patients with PDAC and a history of other primary malignancies had significantly poorer overall survival than their counterparts, despite no differences in disease-free survival.
引用
收藏
页数:7
相关论文
共 50 条
  • [31] Outcomes of Distal Pancreatectomy for Pancreatic Ductal Adenocarcinoma in the Netherlands: A Nationwide Retrospective Analysis
    de Rooij, Thijs
    Tol, Johanna A.
    van Eijck, Casper H.
    Boerma, Djamila
    Bonsing, Bert A.
    Bosscha, Koop
    van Dam, Ronald M.
    Dijkgraaf, Marcel G.
    Gerhards, Michael F.
    van Goor, Harry
    van der Harst, Erwin
    de Hingh, Ignace H.
    Kazemier, Geert
    Klaase, Joost M.
    Molenaar, I. Quintus
    Patijn, Gijs A.
    van Santvoort, Hjalmar C.
    Scheepers, Joris J.
    van der Schelling, George P.
    Sieders, Egbert
    Busch, Olivier R.
    Besselink, Marc G.
    ANNALS OF SURGICAL ONCOLOGY, 2016, 23 (02) : 585 - 591
  • [32] Skeletal metastases in advanced pancreatic ductal adenocarcinoma (PDAC): A retrospective analysis.
    Puri, Akshjot
    Chang, John
    Dragovich, Tomislav
    Lucente, Patricia
    Kundranda, Madappa N.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [33] Proteomic analysis of pancreatic ductal adenocarcinoma
    Meleady, Paula
    Rahman, Rozana Abdul
    Henry, Michael
    Moriarty, Michael
    Clynes, Martin
    EXPERT REVIEW OF PROTEOMICS, 2020, 17 (06) : 453 - 467
  • [34] Molecular and clinical characteristics of patients with KRAS mutated pancreatic ductal adenocarcinoma
    Xiao, Alexander Hua
    Desai, Aakash
    Halfdanarson, Thorvardur Ragnar
    Alberts, Steven R.
    McWilliams, Robert R.
    Mahipal, Amit
    Bekaii-Saab, Tanios S.
    Shi, Qian
    Carr, Ryan Michael
    Ma, Wen Wee
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [35] Clinical relevance of somatic and germline alterations in patients with pancreatic ductal adenocarcinoma
    Wang, F.
    Liu, Q.
    Li, X.
    Yuan, H.
    Ma, T.
    Liu, R.
    Zhao, Z.
    Zhang, X.
    ANNALS OF ONCOLOGY, 2020, 31 : S946 - S946
  • [36] Diffuse pancreatic ductal adenocarcinoma: Characteristic imaging features
    Choi, Young Jun
    Byun, Jae Ho
    Kim, Ji-Youn
    Kim, Myung-Hwan
    Jang, Se Jin
    Ha, Hyun Kwon
    Lee, Moon-Gyu
    EUROPEAN JOURNAL OF RADIOLOGY, 2008, 67 (02) : 321 - 328
  • [37] Immune features of the peritumoral stroma in pancreatic ductal adenocarcinoma
    Ahmed, Azaz
    Klotz, Rosa
    Koehler, Sophia
    Giese, Nathalia
    Hackert, Thilo
    Springfeld, Christoph
    Jaeger, Dirk
    Halama, Niels
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [38] Clinical features and survival of patients with multiple primary malignancies
    Xin-Kun Wang
    Min-Hang Zhou
    World Journal of Clinical Cases, 2021, 9 (34) : 10484 - 10493
  • [39] Clinical features and survival of patients with multiple primary malignancies
    Wang, Xin-Kun
    Zhou, Min-Hang
    WORLD JOURNAL OF CLINICAL CASES, 2021, 9 (34) : 10484 - 10493
  • [40] Clinical Potential of MicroRNAs in Pancreatic Ductal Adenocarcinoma
    Steele, Colin W.
    Oien, Karin A.
    McKay, Colin J.
    Jamieson, Nigel B.
    PANCREAS, 2011, 40 (08) : 1165 - 1171